Oncotelic Therapeutics, Inc.
Oncotelic Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition on December 15, 2028. There is 1 upcoming event on record.
Cash runway is approximately 3.6 months based on the most recent reported cash position and quarterly operating burn as of 2025-09-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| December 15, 2028 | OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition | Trial Milestone | Phase 2 |
Track OTLC alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open OTLC in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.